| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Insulin degludec/liraglutide (IDegLira) |
| Brand | Xultophy® |
| Indication | For the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control. |
| Assessment Process | |
| Rapid review commissioned | 19/09/2016 |
| Rapid review completed | 17/10/2016 |
| Rapid review outcome | Full pharmacoeconomic assessment recommended at the submitted price. |
The HSE has approved reimbursement; July 2019.
